Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Recurrence 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Large Granular Lymphocytic 1Leukemia 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Rituximab 58Cyclophosphamide 40fludarabine phosphate 27fludarabine 21Lenalidomide 19Mycophenolic Acid 17idelalisib 16Antilymphocyte Serum 16Cyclosporine 15Tacrolimus 13Radiotherapy 13Filgrastim 13venetoclax 12umbralisib 12Whole-Body Irradiation 12Busulfan 12Bendamustine Hydrochloride 12ublituximab 11ibrutinib 11Methotrexate 11Peripheral Blood Stem Cell Transplantation 10Alemtuzumab 10obinutuzumab 9Melphalan 9Chlorambucil 8Bortezomib 8thymoglobulin 7ofatumumab 7Etoposide 7Clofarabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Lymphocytic, Chronic, B-Cell × tipifarnib × Clear all
NCT00360776 2017-04-05

Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia

National Cancer Institute (NCI)

Phase 2 Terminated
25 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Large Granular Lymphocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡